End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.01 EUR | -.--% | -.--% | -.--% |
2021 | Ovoca Bio : Enrolls First Patient in Phase 2 Trial for Hypoactive Sexual Desire Disorder Treatment | MT |
Sales 2021 | - | Sales 2022 | - | Capitalization | 4.89M 4.53M |
---|---|---|---|---|---|
Net income 2021 | -5M -4.63M | Net income 2022 | -5M -4.63M | EV / Sales 2021 | - |
Net cash position 2021 | 6.59M 6.11M | Net cash position 2022 | 3.7M 3.43M | EV / Sales 2022 | - |
P/E ratio 2021 |
-2.23
x | P/E ratio 2022 |
-0.87
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 47.54% |
1st Jan change | Capi. | |
---|---|---|
+8.38% | 115B | |
+10.13% | 105B | |
-11.69% | 22.71B | |
+2.21% | 21.83B | |
-10.88% | 18.18B | |
-41.90% | 16.52B | |
-16.00% | 16.01B | |
+2.28% | 14.14B | |
+20.54% | 10.71B |
- Stock Market
- Equities
- OVXA Stock
- OVXA Stock